# Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer

> **NCT04642664** · PHASE2 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 22 (actual)

## Conditions studied

- Biliary Tract Cancer
- Cholangiocarcinoma
- Biomarker
- Hepatobiliary Neoplasm

## Interventions

- **DRUG:** Apatinib plus Camrelizumab

## Key facts

- **NCT ID:** NCT04642664
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04642664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04642664, "Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04642664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*